Drug Trial Radar · NCT07722611
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Jun 25, 2032
Study completion Nov 30, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, also called MK-3543, can treat PV. In this study, researchers will compare bomedemstat to 2 usual treatments for PV. The goal of this study is to learn if more participants who take bomedemstat reach healthy blood cell counts and avoid major health problems from PV, compared to those who receive a usual treatment.
Conditions
- Polycythemia Vera
Interventions
BomedemstatDrug
Oral Capsule
RuxolitinibDrug
Oral Tablet
Ropeginterferon alfa-2bDrug
Subcutaneous Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinicohematologic Response (CHR) RateTime frame: Up to approximately Week 52
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Medical Oncology Hematology Consultants (MOHC) ( Site 8002)
Newark, Delaware · Recruiting
Maryland Oncology Hematology (MOH) ( Site 8001)
Columbia, Maryland · Recruiting
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8004)
Eugene, Oregon · Recruiting
University of Virginia ( Site 5031)
Charlottesville, Virginia · Recruiting
Princess Margaret Cancer Centre ( Site 4002)
Toronto, Ontario, Canada · Recruiting
Soroka Medical Center ( Site 2607)
Beersheba, Israel · Recruiting
Hadassah Medical Center ( Site 2604)
Jerusalem, Israel · Recruiting
Sourasky Medical Center ( Site 2602)
Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.